Viewing Study NCT05249959

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:46 PM
Ignite Modification Date: 2025-12-30 @ 2:10 AM
Study NCT ID: NCT05249959
Status: RECRUITING
Last Update Posted: 2025-08-08
First Post: 2022-02-03
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
Sponsor: Fondazione Italiana Linfomi - ETS
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsed Mantle Cell Lymphoma View
None Refractory Mantle Cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Relapsed/Refractory Mantle Cell Lymphoma (MCL) View
None ADCT-402 (loncastuximab tesirine) View
None BTKi (Bruton Tyrosine Kinase inhibitors) - treated View
None BTKi (Bruton Tyrosine Kinase inhibitors) intolerant View